Filing Details

Accession Number:
0001493152-18-009008
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-20 12:12:56
Reporting Period:
2018-06-14
Accepted Time:
2018-06-20 12:12:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1133416 Galectin Therapeutics Inc GALT Pharmaceutical Preparations (2834) 043562325
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1260641 C James Czirr C/O Galectin Therapeutics, Inc.
4960 Peachtree Ind. Blvd., Suite 240
Norcross, GA 30071
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-06-14 31,860 $7.99 2,769,786 No 4 S Indirect See footnote
Common Stock Disposition 2018-06-14 44,525 $8.48 2,725,261 No 4 S Indirect See footnote
Common Stock Disposition 2018-06-15 15,475 $8.47 2,709,786 No 4 S Indirect See footnote
Common Stock Disposition 2018-06-18 60,000 $9.06 2,649,786 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. Common shares should pursuant to a trading plan pursuant to Rule 10b5-1. Price represents the gross sales price less commissions and brokerage fees.
  2. The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein.